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Background: Neurological manifestations of West Nile virus infection include meningitis, encephalitis and acute
flaccid paralysis. Typically, West Nile virus-associated acute flaccid paralysis is characterized by acute and rapidly
progressing limb weakness, occurring early in the course of the disease.
Case presentation: We report a patient of Yemenite descent who developed West Nile virus-encephalitis and
poliomyelitis two weeks following treatment with rituximab for B cell lymphoma, and delayed encephalitis with
ascending demyelinating polyneuropathy 6 months later. Diagnosis of the first episode was based on a high West
Nile virus copy number in the blood polymerase chain reaction. During the second episode the patient developed
encephalitis and flaccid asymmetric quadriparesis, accompanied by high IgM anti-West Nile virus titers in the blood
and cerebrospinal fluid.
Conclusion: The delayed polyneuropathy post-West Nile virus infection and encephalitis/poliomyelitis may be
related to reactivation of the virus or to a delayed autoimmune (post-infectious) process, possibly accelerated by
the recovering B-cell humoral immunity, 6 months after treatment with rituximab. This case depicts the complexities
of the immune responses and their reconstitution following monoclonal antibody treatment and the diversity of
neurological syndromes associated with West Nile virus infection.
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Only less than one percent of individuals infected by the
West-Nile virus (WNV) develop neurological manifesta-
tions [1]. These include meningitis, encephalitis, and acute
flaccid paralysis (AFP). Delayed flaccid paralysis/polyradi-
culitis has also been described several weeks following
WNV-infection [2]. WNV anterior poliomyelitis usually
occurs early in the course of the infection. Jackson et al.
[2] recently described four atypical cases of WNV-
poliomyelitis. In one of them the onset of poliomyelitis
was delayed (several weeks following the initial infection)
and three patients suffered from relapsing limb weakness
following a period of clinical remission. The authors sug-
gested that the delayed WNV-poliomyelitis could be ex-
plained by a chronic infection or delayed neuroinvasion.* Correspondence: Karus@Cc.Huji.Ac.Il
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article, unless otherwise stated.This is supported by the finding that WNV-ribonucleic
acid may be detected in the urine of convalescent patients
up to 7 years following infection [3]. However, attempts to
grow the virus from the urine samples of these patients
were not successful. Additional studies are necessary to
determine the significance of this finding.
We describe here a patient who developed WNV-
encephalitis and poliomyelitis two weeks following treat-
ment with rituximab for B cell lymphoma, and delayed
ascending demyelinating polyneuropathy 6 months later.
Case representation
A 57 year- old- male, of Yemenite descent, was admitted
to the Department of Neurology at Hadassah University
Hospital due to encephalitis. B-cell lymphoma had been
diagnosed one year earlier and after a year of management
with cytotoxic medications, it was decided to start treat-
ment with rituximab. Two weeks following initiation of ri-
tuximab, the patient suffered from high fever and confusion.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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right leg. The laboratory and microbiological evaluation
was unremarkable, except for the blood-polymerase chain
reaction (PCR), which was positive for WNV (examined
3 days after the initial presentation). The blood and cere-
brospinal fluid (CSF) were negative for WNV antibodies,
both IgG and IgM, possibly due to defective humoral re-
sponses caused by the treatment with rituximab. CSF ana-
lysis showed 9 white blood cells and an elevated protein
level of 850 mg per liter. A diagnosis of WNV-encephalitis/
poliomyelitis was made. The patient recovered from the en-
cephalitis with a residual mild weakness in his right leg and
a mild cognitive impairment.
Six months later, the patient was re-hospitalized due to
vomiting, instability of gait and a fever of 38°C. An ascend-
ing paralysis developed gradually, starting symmetrically
in the legs and involving (four days later) the hands.
Neurological examination revealed dysarthric speech,
bilateral horizontal nystagmus, more evident to the right,
weakness of the bulbar muscles, as well as the neck
flexors, weak reflexes of the right hand but well-retained
in the other limbs, and a right plantar extension reflex,
accompanied by prominent frontal release signs. He had
truncal ataxia and bilateral dysmetria. His mini-mental
score was 27/30, with marked slowness of thinking.
The laboratory workup was unremarkable, excluding a
sedimentation rate of 84.
Serological tests for mycoplasma, Rickettsia conorii,
Salmonella typhi, HIV, HTLV and chlamydia were nega-
tive, as well as for anti-GM1 antibodies. A lumbar punc-
ture revealed mild CSF pleocytosis (12 lymphocytes) and
an elevated CSF protein level (625 mg/l). The serology
for WNV showed consistently high titers of IgM anti-
WNV antibodies, whereas the IgG anti-WNV antibodies
remained negative. The PCR for WNV in the blood, CSF
and urine was negative. A CSF-PCR for a panel of en-
teroviruses and microbiological tests for fungi, were all
negative. Neuroimaging, (CT and MRI) of the brain and
cervical spinal cord did not reveal any pathology. A bone
marrow biopsy and PET-CT imaging did not show re-
currence of the lymphoma.
The EMG tests showed prolonged motor latencies and
slow conduction velocities, with dispersion in multiple
nerves of the upper limbs and conduction block in the
nerves of the legs, supporting the diagnosis of demyelinat-
ing polyneuropathy. Following treatment with 5 doses of
intravenous immunoglobulins (IVIG) and a high dose of
intravenous methylprednisolone (IVMP), there was remark-
able improvement of the paralytic disease. The patient died
two years following the reported events of unrelated causes.
Conclusions
In our case, a delayed ascending demyelinating polyneur-
opathy with flaccid asymmetric quadriparesis developed6 months following WNV-infection with encephalitis and,
possibly, mild poliomyelitis (right leg paresis). Polyradiculi-
tis has been reported up to few weeks following WNV-
infection, but such a delayed onset is very unusual. Possible
explanations for this recurrence (and expansion) of the
neurological involvement caused by WNV may include
persistent/chronic viral infection of the central and periph-
eral nervous systems or reactivation of the virus [3]) and
secondary immune-mediated (post-viral) mechanisms. The
latter may be related to the rebound of antibody reactivity
during the recovery of the suppressed humoral immune re-
sponses, 6 months after treatment with rituximab. The
high IgM anti-WNV antibody titers (which were negative
initially) may support this possibility and indicate an acute,
delayed immunological reaction.
Alternatively, the ascending polyneuropathy may rep-
resent Acute Inflammatory Demyelinating Polyneurop-
athy (AIDP) not necessarily directly caused by the WNV
but possibly related to the treatment with rituximab. De-
velopment of AIDP and of autoimmune diseases follow-
ing treatment with cytotoxic or immunosuppressive
medications, including rituximab, has been reported in
the literature [4,5]. This paradoxical phenomenon depicts
and underlines the intricate and delicate interactions in-
side the immune system network. Immunosuppression
may occasionally affect predominantly the regulatory or
suppressor lymphocytes and allow the expansion of other-
wise suppressed auto-reactive lymphocytes, leading to the
break of self tolerance and the development of auto-
immune disease [6]. Specifically, in the case of monoclonal
antibodies such as rituximab, the delayed development of
autoimmune syndromes may be related to the reconstitu-
tion phase of the B-cells, which during their recovery may
cause a strong rebound of antibody production, cap-
able of breaking self tolerance. The negative CSF PCR
for WNV is a puzzling finding that advocates against
the possibility of a persistent infection. It thus seems
more likely that the delayed neurological syndrome in
our case was caused by an immune-mediated mechan-
ism similar to that involved in the pathogenesis of
other post-viral syndromes. Molecular mimicry plays
the major role in the pathogenesis of such post-viral
syndromes. A typical example of such an autoimmune
disease is post-infectious AIDP, which is often caused by
an immune response that initially targets Campylobacter
jejuni [7].
The possibility that the polyneuropathy in our case
was (directly or indirectly) related to the lymphoma is
highly unlikely, due to the fact that there were no signs
of reactivation of the disease in the PET-scan and no
malignant lymphoma cells were found in the CSF (nega-
tive immunoglobulin gene rearrangement in the CSF).
Also, anti- Hu antibodies, indicative of a paraneoplastic
syndrome were not present.
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by Levi et al. [8] in a patient who developed rapid, ful-
minant WNV meningoencephalitis 6 months following
rituximab treatment and succumbed.
In summary, it seems likely that in the present case, the
delayed flaccid paralysis and ascending polyneuritis, in the
absence of evidence of chronic persistent neurological in-
fection with WNV, was most probably caused by an im-
mune reconstitution syndrome, similar to that described
in HIV patients or following organ transplantation and
possibly accelerated by the recovering B-cell humoral im-
munity, 6 months after treatment with rituximab.
Consent
Written informed consent was obtained from the patient’s
next of kin for publication of this Case Report and any ac-
companying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
Abbreviations
WNV: West Nile virus; AFP: Acute flaccid paralysis; CSF: Cerebrospinal fluid;
PCR: Polymerase chain reaction.; IVIG: Intravenous immunoglobulins;
IVMP: Intravenous methylprednisolone.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AH and DK conceived of the study, and participated in its design and
coordination and helped to draft the manuscript. Both authors read and
approved the final manuscript.
Acknowledgements
We thank Dr. Alexandra Mahler for her editorial assistance.
Received: 3 March 2014 Accepted: 6 November 2014
Published: 26 November 2014
References
1. Mostashari F, Bunning M, Kitsutani P, Singer D, Nash D, Cooper M, Katz N,
Liljebjelke K, Biggerstaff B, Fine A, Layton M, Mullin S, Johnson A, Martin D,
Hayes E, Campbell G: Epidemic West Nile Encephalitis, New York, 1999:
results of a household-based seroepidemiological survey. Lancet 1999,
2001(358):261–264.
2. Sejvar J, Davis L, Szabados E, Jackson A: Delayed-onset and recurrent limb
weakness associated with West Nile virus infection. J Neurovirol 2010,
16(1):93–100.
3. Murray K, Walker C, Herrington E, Lewis J, Mccormick J, Beasley D, Tesh R,
Fisher-Hoch S: Persistent Infection with West Nile virus years after initial
infection. J Infect Dis 2010, 201(1):2–4.
4. Jaso R, Sierra M, Calleja J, Valero C, Pascual J: Guillain-Barré Syndrome after
rituximab in a patient with idiopathic thombocytopenic purpura: a
causal association? J Neurol 2010, 257(3):488–489.
5. Terenghi F, Ardolino G, Nobile-Orazio E: Guillain-Barré syndrome after
combined chop and rituximab therapy in non-Hodgkin lymphoma.
J Peripher Nerv Syst 2007, 12:142–143.
6. Tn C, Arnold D: The effect of rituximab on humoral and cell mediated
immunity and infection in the treatment of autoimmune diseases. Br J
Haematol 2010, 149(1):3–13.7. Heikema A, Bergman M, Richards H, Crocker P, Gilbert M, Samsom J, Van
Wamel W, Endtz H, Van Belkum A: Characterization of the specific
interaction between Sialoadhesin and Sialylated campylobacter jejuni.
Infect Immun 2010, 78(7):3237–3246.
8. Me L, Quan D, Ho J, Kleinscmidt D, Tyler K, Gracia T: Impact of rituximab-
associated B-cell defects on West-Nile virus meningoencephalitis in solid
organ transplant recipients. Clin Transplant 2010, 24:223–228.
doi:10.1186/1756-0500-7-852
Cite this article as: Honig and Karussis: Delayed-onset flaccid paralysis
related to west Nile virus reactivation following treatment with
rituximab: a case report. BMC Research Notes 2014 7:852.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
